KLRG1, Another Opportunity for a Breakthrough in MTCL.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing mAbs compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T cells and avoid the toxicity concerns with previous agents. See related article by Assatova et al., p. 2514.

Keyphrases

single cell
structural basis
cell therapy
oxidative stress
type diabetes
stem cells
metabolic syndrome
mesenchymal stem cells
binding protein
bone marrow
glycemic control